Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$33.40
+2.3%
$34.15
$29.31
$61.38
$3.90B0.591.54 million shs1.43 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$284.98
+0.7%
$293.01
$200.63
$377.46
$6.28B-1.08359,513 shs298,118 shs
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$199.92
$198.62
$23.27
$199.98
$9.56B-0.49913,102 shsN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$120.16
+1.8%
$124.99
$115.94
$249.91
$5.22B1.1629,645 shs458,141 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.65%-3.37%+6.88%-26.73%-39.01%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.96%-0.73%+5.77%-17.57%+1.64%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00%0.00%0.00%0.00%0.00%
Teleflex Incorporated stock logo
TFX
Teleflex
+0.08%-2.46%-2.34%-15.24%-41.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.2406 of 5 stars
4.53.00.04.61.50.80.0
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.1287 of 5 stars
3.41.00.04.61.93.30.6
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
4.6321 of 5 stars
3.04.02.53.92.71.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.92112.34% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.89
Moderate Buy$420.6347.60% Upside
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00
N/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
2.09
Hold$164.6337.00% Upside

Current Analyst Ratings Breakdown

Latest RXDX, CYTK, MDGL, and TFX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $80.00
5/5/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$140.00 ➝ $137.00
5/5/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$191.00 ➝ $173.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M215.97N/AN/A($1.15) per share-29.04
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$180.13M35.12N/AN/A$34.59 per share8.24
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$6.81M1,403.55N/AN/A$16.12 per share12.40
Teleflex Incorporated stock logo
TFX
Teleflex
$3.05B1.74$25.84 per share4.65$92.11 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
-$141.75M-$3.52N/AN/AN/A-3,768.76%-33.50%-29.59%N/A
Teleflex Incorporated stock logo
TFX
Teleflex
$69.68M$3.1737.917.921.854.96%14.73%8.79%7/30/2025 (Estimated)

Latest RXDX, CYTK, MDGL, and TFX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
5/1/2025Q1 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million
5/1/2025Q1 2025
Teleflex Incorporated stock logo
TFX
Teleflex
$2.88$2.91+$0.03$2.07$699.37 million$700.67 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.361.13%N/A42.90%N/A

Latest RXDX, CYTK, MDGL, and TFX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/12/2025
Teleflex Incorporated stock logo
TFX
Teleflex
quarterly$0.341.09%5/20/20255/20/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.17
5.91
5.58
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.04
37.56
37.56
Teleflex Incorporated stock logo
TFX
Teleflex
0.44
2.28
1.32

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
92.66%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.40%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
21.50%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
3.40%
Teleflex Incorporated stock logo
TFX
Teleflex
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million115.37 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million17.43 millionOptionable
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
9747.81 million46.19 millionNot Optionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,10044.19 million43.57 millionOptionable

Recent News About These Companies

Teleflex Incorporated stock logo
Teleflex (NYSE:TFX) Reaches New 1-Year Low - What's Next?
Teleflex (NYSE:TFX) Upgraded to "Buy" at Wall Street Zen
Brokerages Set Teleflex Incorporated (NYSE:TFX) PT at $164.63
Teleflex Incorporated stock logo
Wall Street Zen Upgrades Teleflex (NYSE:TFX) to "Buy"
Teleflex has positive Arrow catheter data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$33.40 +0.76 (+2.33%)
Closing price 04:00 PM Eastern
Extended Trading
$33.40 +0.01 (+0.01%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$284.98 +1.99 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$285.99 +1.01 (+0.36%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Prometheus Biosciences stock logo

Prometheus Biosciences NASDAQ:RXDX

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Teleflex stock logo

Teleflex NYSE:TFX

$120.16 +2.10 (+1.78%)
Closing price 03:59 PM Eastern
Extended Trading
$120.08 -0.08 (-0.07%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.